Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evelina Martinenaite

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Journal for Immunotherapy of Cancer|February 28, 2024
TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblastsMaria Perez-Penco, Lucia Lara de la Torre, Inés Lecoq, et al.
Oncoimmunology|September 20, 2018
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutationMia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, et al.
Clinical and Experimental Immunology|February 18, 2025
Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytesCecilie Oelvang Madsen, Marta Velasco Santiago, Evelina Martinenaite, et al.
Oncoimmunology|February 26, 2024
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cellsHannah Jorinde Glöckner, Evelina Martinenaite, Thomas Landkildehus Lisle, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2019
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitopeEvelina Martinenaite, Shamaila Munir Ahmad, Simone Kloch Bendtsen, et al.
Oncoimmunology|May 12, 2015
Spontaneous presence of FOXO3-specific T cells in cancer patientsStine Kiaer Larsen, Shamaila Munir Ahmad, Manja Idorn, et al.
Oncoimmunology|September 14, 2016
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccineShamaila Munir Ahmad, Evelina Martinenaite, Morten Hansen, et al.
Frontiers in Immunology|November 4, 2022
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trialCathrine Lund Lorentzen, Evelina Martinenaite, Julie Westerlin Kjeldsen, et al.
Oncoimmunology|December 22, 2016
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironmentEvelina Martinenaite, Shamaila Munir Ahmad, Morten Hansen, et al.
Oncoimmunology|September 2, 2022
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironmentInés Lecoq, Katharina L Kopp, Marion Chapellier, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|February 28, 2024
TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblastsMaria Perez-Penco, Lucia Lara de la Torre, Inés Lecoq, et al.
Oncoimmunology|September 20, 2018
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutationMia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, et al.
Clinical and Experimental Immunology|February 18, 2025
Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytesCecilie Oelvang Madsen, Marta Velasco Santiago, Evelina Martinenaite, et al.
Oncoimmunology|February 26, 2024
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cellsHannah Jorinde Glöckner, Evelina Martinenaite, Thomas Landkildehus Lisle, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2019
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitopeEvelina Martinenaite, Shamaila Munir Ahmad, Simone Kloch Bendtsen, et al.
Oncoimmunology|May 12, 2015
Spontaneous presence of FOXO3-specific T cells in cancer patientsStine Kiaer Larsen, Shamaila Munir Ahmad, Manja Idorn, et al.
Oncoimmunology|September 14, 2016
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccineShamaila Munir Ahmad, Evelina Martinenaite, Morten Hansen, et al.
Frontiers in Immunology|November 4, 2022
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trialCathrine Lund Lorentzen, Evelina Martinenaite, Julie Westerlin Kjeldsen, et al.
Oncoimmunology|December 22, 2016
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironmentEvelina Martinenaite, Shamaila Munir Ahmad, Morten Hansen, et al.
Oncoimmunology|September 2, 2022
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironmentInés Lecoq, Katharina L Kopp, Marion Chapellier, et al.
Pageof 3